Related references
Note: Only part of the references are listed.Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3
Shafei Wu et al.
FRONTIERS IN IMMUNOLOGY (2021)
Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
Xin-yu Ren et al.
FRONTIERS IN ONCOLOGY (2021)
Ligand-Installed Nanocarriers toward Precision Therapy
Peng Mi et al.
ADVANCED MATERIALS (2020)
Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis
Satu Tiainen et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y. Ho et al.
CANCER (2020)
The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting
Nahla M. Badr et al.
PATHOBIOLOGY (2020)
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour -agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
T. Yoshino et al.
ANNALS OF ONCOLOGY (2020)
Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer
Lei Zhou et al.
NANO LETTERS (2020)
Oncolytic vesicular stomatitis virus-based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+ T-cell functionality
Seyedeh-Raheleh Niavarani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Multifunctional Smart Yolk-Shell Nanostructure with Mesoporous MnO2 Shell for Enhanced Cancer Therapy
Hongjun Zhuang et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
Alan Chen Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity
Jingjing Liang et al.
SCIENCE ADVANCES (2020)
An Intelligent Biomimetic Nanoplatform for Holistic Treatment of Metastatic Triple-Negative Breast Cancer via Photothermal Ablation and Immune Remodeling
Yuanyuan Cheng et al.
ACS NANO (2020)
Fighting Immune Cold and Reprogramming Immunosuppressive Tumor Microenvironment with Red Blood Cell Membrane-Camouflaged Nanobullets
Zhe Yang et al.
ACS NANO (2020)
The viral approach to breast cancer immunotherapy
Atefeh Arab et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
Di (Maria) Jiang et al.
Oncotarget (2019)
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer
H. Vihervuori et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles
Yeteng Zhong et al.
NATURE BIOTECHNOLOGY (2019)
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)
Stephen Chia et al.
ONCOLOGIST (2019)
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
Zi-Qi Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer
Ying Tian et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Yan Liu et al.
AGING-US (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients
Yuhan Zhang et al.
CANCER BIOLOGY & MEDICINE (2019)
ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models
Lars Wallstabe et al.
JCI INSIGHT (2019)
PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation
Megan Morisada et al.
ONCOIMMUNOLOGY (2018)
Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis
Reyhane Chamani et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Immunotherapeutic interventions of Triple Negative Breast Cancer
Zehuan Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
被撤回的出版物: Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway (Retracted article. See vol. 15, pg. 10735, 2021)
Jianqin Lu et al.
ACS NANO (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Tiara T. Byrd et al.
CANCER RESEARCH (2018)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical validity and Utility of Tumor-infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
Lironne Wein et al.
FRONTIERS IN ONCOLOGY (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
X. Yu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L. McArthur et al.
CLINICAL CANCER RESEARCH (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
Lewis Zhichang Shi et al.
NATURE COMMUNICATIONS (2016)
Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses
Yasuharu Nishimura et al.
CANCER SCIENCE (2015)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Nanooncology: The Future of Cancer Diagnosis and Therapy
Avnesh S. Thakor et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Image-guided Thermal Ablation of Tumors Increases the Plasma Level of Interleukin-6 and Interleukin-10
Joseph P. Erinjeri et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2013)
Changes in interleukin-1β and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections
Fateh Ahmad et al.
AMERICAN JOURNAL OF SURGERY (2010)
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Chrystelle Brignone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer
Anna Maria Fietta et al.
HUMAN IMMUNOLOGY (2009)
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
E. Schmitt et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Share Paper
